Latest Articles

  • Benzodiazepines: Caught between patient needs and guidelines
    Jasleen Kaur, MD, Vania Modesto-Lowe, MD, MPH and Margaret M. Chaplin, MD
    Cleveland Clinic Journal of Medicine September 2025, 92 (9) 531-535; DOI: https://doi.org/10.3949/ccjm.92a.25019

    Negative sentiment about benzodiazepines has intensified in recent years, and there is increasing emphasis on deprescribing even for people who have had no ill effects from them.

  • Collaborative musculoskeletal care: The role for chiropractors
    Samuel M. Schut, DC, Logan J. Benjamin, DC, MPH and Timothy J. Williamson, DC, MS
    Cleveland Clinic Journal of Medicine September 2025, 92 (9) 550-554; DOI: https://doi.org/10.3949/ccjm.92a.25014

    Integrating chiropractors into multidisciplinary care settings can help support guideline-concordant care and may free up internists to see more patients with other problems.

  • Flexibility is warranted in applying prescribing guidelines
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine September 2025, 92 (9) 520-521; DOI: https://doi.org/10.3949/ccjm.92b.09025

    Discontinuation of benzodiazepines in chronic users may be associated with a small increase in mortality and a higher risk of adverse events, especially in the short term after cessation.

  • An overview of over-the-counter contraceptives: Spotlight on daily oral norgestrel
    Rujuta Takalkar, BS, Andrea Lorenzo, MD, MS and Suneela Vegunta, MD, NCMP
    Cleveland Clinic Journal of Medicine September 2025, 92 (9) 572-576; DOI: https://doi.org/10.3949/ccjm.92a.24108

    Oral norgestrel, the first daily oral contraceptive pill available over the counter in the United States, is a safe, effective addition to existing over-the-counter contraceptive options.

  • Cerebrovascular complications in infective endocarditis: Challenges and considerations in management
    Cerebrovascular complications in infective endocarditis: Challenges and considerations in management
    Vikyath Satish, MD, Maisha Maliha, MD, Abhyuday Chauhan, MD, Nieves del Mar Morales-Gomez, MD, Safwan Gaznabi, MD, Daniel Lorenzatti, MD, Justin Johannesen, MD, Carlos A. Gongora, MD, Annalisa Filtz, MD, Mario J. Garcia, MD, Leandro Slipczuk, MD, PhD and Aldo L. Schenone, MD
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 491-501; DOI: https://doi.org/10.3949/ccjm.92a.24087

    Although the cerebrovascular complications of infective endocarditis such as ischemic strokes and intracranial hemorrhages are common and serious, data remain scarce regarding how best to prevent, predict, and manage them.

  • Evolving paradigms in hypertension management: Fixed-dose single-pill combinations and future therapies
    George Thomas, MD
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 471-474; DOI: https://doi.org/10.3949/ccjm.92a.25034

    Despite the availability of effective medications, blood pressure control rates have declined over the past decade, underscoring the need for improved treatment approaches.

  • Does my patient need testing for PFAS ‘forever chemicals’?
    Philip Zuccaro, BS, Damaskini Valvi, MD, MPH, PhD and Vasilis Vasiliou, PhD
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 463-465; DOI: https://doi.org/10.3949/ccjm.92a.24082

    Any patient has the right to undergo blood testing for PFAS, but the limitations of testing must be discussed with the patient.

  • Should I consider single-pill combination antihypertensive therapy for my patient with high blood pressure?
    Maximilian C. Volk, DO, Ahmad Safdar, MD and Luke J. Laffin, MD
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 467-470; DOI: https://doi.org/10.3949/ccjm.92a.25002

    For many patients, starting treatment with a single-pill combination should be considered for the initial management of hypertension.

  • Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce
    CME article
    Adi E. Mehta, MD, Laura D. Lomeli, BA and Kevin M. Pantalone, DO, ECNU
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 483-489; DOI: https://doi.org/10.3949/ccjm.92a.24113

    Early trials suggested a link between GLP-1 receptor agonists and pancreatitis, but recent large meta-analyses do not support a class-wide risk.

  • Newer diabetes drugs: Surprising shared benefits and unique side effects
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine August 2025, 92 (8) 457-458; DOI: https://doi.org/10.3949/ccjm.92b.08025

    The shared beneficial effects of the SGLT2 inhibitors and the GLP-1 receptor agonists, drugs with distinct mechanisms of action, may have an anti-inflammatory explanation.

Pages